Medline Bed Death Toll Climbs to Seven After FDA Warning
MDLN sits 27% above its 52-week low of $31.37.
Summary
The death count tied to Medline-branded beds has risen to seven, up from the two deaths the company reported when the FDA issued a public warning on October 29. That is a materially worse outcome than the figure regulators and investors had been working with. Medline already said on October 21 it is exiting the entire Medline Brand bed business after a voluntary field action, with estimated costs of up to a disclosed cap, so the financial exposure was partly quantified — but a rising fatality count raises the odds of expanded recalls, litigation and further regulatory action beyond the three unresolved FDA warning letters already disclosed in the Q3 10-Q. The stock fell 13% on October 6 when product quality issues first surfaced and a securities fraud investigation was opened; this headline adds to that risk cluster rather than resolving it.
At the time of this announcement, MDLN was trading at $39.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.9B. The 52-week trading range was $31.37 to $50.88. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.